30 April 1999
Application of nonspecific bronchial challenge tests-when, how and why?
Jerzy Mosiewicz, Wojciech Myśliński, Maria Jaszyna, Janusz HanzlikMed Sci Monit 1999; 5(3): RA591-595 :: ID: 505069
Abstract
A term 'bronchial hyperreactivity' refers to abnormally strong bronchospasm caused by many various factors that in normal conditions are not able to produce such response. In practice the assessment of bronchial reactivity is based on bronchial challenge tests. The aim of our study is to present currently used bronchial provocation tests, consisted of assessment of initial pulmonary function parameters, administration of a bronchospastic challenging agent, measurement and interpretation of observed changes. Histamine and methacholine are the most commonly used provocation agents. Safety, usefulness, nonallergenic activity of these agents allows obtained results to be repeatable. Bronchial provocation tests may be used to confirm existing bronchial hyperreactivity but also to evaluate 'severity' of asthma and its response to pharmacological treatment. Positive tests correspond with diagnosis of asthma but have less diagnostic value because they can also be positive in several other diseases such as e.g. COPD, cystic fibrosis, bronchiectasis, sarcoidosis, viral respiratory tract infections, heart failure or reflux oesophagitis. Provocation tests are particularly important in cases of bronchial asthma clinically manifested by cough without wheezing and flow limitation syndrome. Properly performed bronchial provocation tests are safe. Relative contraindications may be diagnosed: history of unexplained urticaria or Quincke's edema, severe airflow obstruction, unstable angina and pregnancy. If initial results of spirometry are normal, bronchospasm will spontaneously regress within 30-45 min. or even within 5 min. after administration of bronchodilators. Symptoms including cough, chest discomfort, breathlessness, sore throat, excessive salivation, headache and dizziness are usually mild and last for several minutes.
Keywords: methacholine, Asthma, Bronchial Hyperreactivity
Editorial
01 March 2025 : Editorial
Editorial: The World Health Organization (WHO) Updated List of Emerging and Potentially Pandemic Pathogens Includes Yersinia pestis as Plague Vaccines Await Clinical TrialsDOI: 10.12659/MSM.948672
Med Sci Monit 2025; 31:e948672
In Press
Database Analysis
Utility of Central Venous Oxygen Saturation Gradient in Predicting Mortality in Dialysis with Catheter AccessMed Sci Monit In Press; DOI: 10.12659/MSM.947298
Clinical Research
Intraoperative Renal Near-Infrared Spectroscopy Monitoring as a Predictor of Renal Outcomes in Cardiac SurgeryMed Sci Monit In Press; DOI: 10.12659/MSM.947462
Clinical Research
Impact of Cholecalciferol Supplementation on Radiotherapy Outcomes in Advanced Cervical CancerMed Sci Monit In Press; DOI: 10.12659/MSM.945964
Clinical Research
Inflammatory Biomarkers in Smokers: Implications for Ligamentum Flavum HypertrophyMed Sci Monit In Press; DOI: 10.12659/MSM.947508
Most Viewed Current Articles
17 Jan 2024 : Review article 7,148,090
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research 702,355
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Mar 2024 : Editorial 27,723
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...DOI :10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
28 Jan 2024 : Review article 21,937
A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and FutureDOI :10.12659/MSM.943912
Med Sci Monit 2024; 30:e943912